Background: Research has demonstrated that Annexin A3 is significantly elevated in breast cancer (BC) patients in comparison to healthy individuals and is negatively associated with general survival and prognosis.
Aim and objectives: To explain the possible function of Annexin A3 in development and metastasis of BC.
Patients & methods: The present research involved 90 female cases that have been chosen from the South Egypt Cancer Institute, Surgery Department, Assiut University at the period from March 2019 to December 2019. They were categorized into 3 groups as follows: 15 patients with benign breast diseases, 55 carcinoma patients and 20 control group
Results: AnnexinA3 had sensitivity of 84.13% and specificity of 66.53% in diagnosis of BC patients. AnnexinA3 showed significant relation with TNM stage, distant metastasis, progesterone receptor. According to relative gene expression of annexin A3, a highly statistically significant variance was observed among control, benign and carcinoma groups. According to clinicopathological features of the BC cases, the most of patients had grade II (74.54%), majority of patients had T3 tumor (41.81%), 22 cases (40%) had N2 regional LN, 47 cases (85.45%) had no distant metastasis, 27 cases (49.09%) had stage III, 36 cases (65.45%) had positive Estrogen receptor, 29 cases (52.72%) had positive progesterone receptor and 27 cases (49.09%) had positive HER2\ neu.
Conclusion: We concluded that AnnexinA3 is a reliable diagnostic marker for breast cancer. Further prospective studies with larger scales are needed for confirming our results.